Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0

作者：

Liegeon, Geoffroy ^{[1
]}

Kaperak, Christopher ^{[1
]}

Friedman, Eleanor E. ^{[1
]}

Djuricich, Paul ^{[2
]}

Dawdani, Alicia ^{[1
]}

Stafford, Kane ^{[2
]}

Plotkin, Sophie ^{[1
]}

Schmitt, Jessica ^{[1
]}

Hazra, Aniruddha ^{[1
]}

Christopoulos, Katerina A. ^{[3
]}

Schneider, John A. ^{[1
]}

Mcnulty, Moira C. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Chicago, IL USA

[2] Univ Chicago, Dept Pharm, Chicago, IL USA

[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;

D O I：

10.1093/ofid/ofaf094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

引用

页数：7

共 50 条

[41] Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
Parikh, Urvi M.
Koss, Catherine A.
Mellors, John W.
CURRENT HIV/AIDS REPORTS, 2022, 19 (05) : 384 - 393
[42] Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
Kim, Yeon-Sook
INFECTION AND CHEMOTHERAPY, 2021, 53 (04): : 686 - 695
[43] Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
Bettonte, Sara
Berton, Mattia
Stader, Felix
Battegay, Manuel
Marzolini, Catia
OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (04):
[44] Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort
Cervo, Adriana
Russo, Antonio
Di Carlo, Domenico
De Vito, Andrea
Fabeni, Lavinia
D'Anna, Stefano
Duca, Leonardo
Colpani, Agnese
Fois, Marco
Zauli, Beatrice
Mancarella, Giulia
Carraro, Anna
Bezenchek, Antonia
Cozzi-Lepri, Alessandro
Santoro, Maria Mercedes
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 34 : 141 - 144
[45] What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
Bettonte, Sara
Berton, Mattia
Marzolini, Catia
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (05) : 243 - 247
[46] A Human Immunodeficiency Virus Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine
Valin, Nadia
Lambert-Niclot, Sidonie
Torres, Emma
Meynard, Jean Luc
Perillaud-Dubois, Claire
Morand-Joubert, Laurence
Lacombe, Karine
CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 196 - 197
[47] Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
Patel, Parul
Teichner, Paula
Elliot, Emilie
Boffito, Marta
Murray, Milena
Polli, Joseph W.
Baker, Mark
Ford, Susan L.
Han, Kelong
Russu, Alberto
Crauwels, Herta
D'Amico, Ronald D.
Spreen, William R.
van Wyk, Jean
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2023, 10
[48] Cabotegravir long-acting for HIV-1 prevention
Andrews, Chasity D.
Heneine, Walid
CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 258 - 263
[49] Rilpivirine long-acting for the prevention and treatment of HIV infection
Ferretti, Francesca
Boffito, Marta
CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 300 - 307
[50] Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation
Wood, Brian R.
Kassaye, Seble G.
Gerstoft, Jan
AIDS, 2023, 37 (04) : 689 - 691

← 1 2 3 4 5 →